Objective:

To explore the connection between glaucoma medications and ocular surface health, emphasizing the importance of patient-doctor communication and adherence to treatment regimens, while addressing both intraocular pressure and ocular surface health.

Key Findings:

• Glaucoma medications can exacerbate ocular surface disease (OSD) due to side effects.
• Preservatives like benzalkonium chloride in medications can harm ocular surface health.
• Patients with pre-existing ocular surface issues are at higher risk of complications.
• Adherence to medication is crucial for controlling IOP and preventing vision loss.
• Patient education significantly impacts adherence and management of OSD.

Interpretation:

Effective management of glaucoma requires addressing both intraocular pressure and the ocular surface health of patients to enhance treatment compliance and quality of life.

Limitations:

• The article does not provide quantitative data on the prevalence of OSD among glaucoma patients.
• Limited discussion on alternative treatment options beyond standard medications.
• Lack of patient perspectives or qualitative data on experiences with OSD.

Conclusion:

Patient education and proactive communication with healthcare providers are essential for managing OSD in glaucoma patients, ensuring better adherence and treatment outcomes, while addressing both IOP and ocular surface health.